Health Trials

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

2

Review clinical trials related to Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 and the combination of MRG003 and HX008 in patients with recurrent or metastatic squamous cell carcinoma of head and neck.

Participants needed: 116
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Miracogen Inc.Updated: Jul 8, 2025Locations: 1
Eligibility criteria

Willing to sign the ICF and follow the requirements specified in the protocol. [+8]

History of 4 or more systemic anti-tumor therapies for the recurrent or metastat... [+24]

Read more
Status: Recruiting

Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N

The main objective of this research is to increase the life expectancy of patients with advanced mouth and throat cancer, by adding avelumab to the standard TPEx treatment. All participants in this research will receive the same treatment which will take place in two phases: * 1st phase chemotherapy + immunotherapy: standard reference treatment (Docetaxel + cisplatin or carboplatin + cetuximab) * 2nd phase immunotherapy: cetuximab combined with avelumab which is the treatment under study.

Participants needed: 70
Trial details
Phase: Phase 2Age: 18-74Biological sex: AllType: InterventionalSponsor: Groupe Oncologie Radiotherapie Tete et CouUpdated: Jan 15, 2025Locations: 1
Eligibility criteria

Adult men and women ≥ 18 years and < 75 years. [+18]

1.Prior systemic chemotherapy for the head and neck carcinoma, except if given a...

Read more